Samuel Mclenachan

35 Stirling Highway
Crawley, WA 6009, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

Characterization of Rcbtb1 Knockout Mice and Evaluation of AAV2-RCBTB1 Gene Replacement Therapy.

Characterization of Rcbtb1 Knockout Mice and Evaluation of AAV2-RCBTB1 Gene Replacement Therapy.

Journal: Translational vision science & technology

Published: July 09, 2026

ABCA4 Versus PRPH2-Associated Retinopathy: Clinical and Electrophysiological Findings.

ABCA4 Versus PRPH2-Associated Retinopathy: Clinical and Electrophysiological Findings.

Journal: Investigative ophthalmology & visual science

Published: April 14, 2026

Autosomal dominant Riggs-type congenital stationary night blindness with fundus sheen and retinal atrophy due to a novel GNAT1 p.Gln200Arg variant.

Autosomal dominant Riggs-type congenital stationary night blindness with fundus sheen and retinal atrophy due to a novel GNAT1 p.Gln200Arg variant.

Journal: Documenta ophthalmologica. Advances in ophthalmology

Published: December 30, 2025

Generation of two induced pluripotent stem cell lines carrying the CDH23 c.1515-12G > A variant.

Generation of two induced pluripotent stem cell lines carrying the CDH23 c.1515-12G > A variant.

Journal: Stem cell research

Published: February 11, 2025

Generation of the induced pluripotent stem cell line LEIi023-A from a rod-cone dystrophy patient carrying the dominant PRPF31 c.267del variant.

Generation of the induced pluripotent stem cell line LEIi023-A from a rod-cone dystrophy patient carrying the dominant PRPF31 c.267del variant.

Journal: Stem cell research

Published: February 07, 2025

Nanoparticle-Based gene therapy strategies in retinal delivery.

Nanoparticle-Based gene therapy strategies in retinal delivery.

Journal: Journal of drug targeting

Published: January 03, 2025

Current approaches for Usher syndrome disease models and developing therapies.

Current approaches for Usher syndrome disease models and developing therapies.

Journal: Frontiers in cell and developmental biology

Published: December 18, 2024

An Optimized Method to Produce Human-Induced Pluripotent Stem Cell-Derived Limbal Stem Cells Easily Adaptable for Clinical Use.

An Optimized Method to Produce Human-Induced Pluripotent Stem Cell-Derived Limbal Stem Cells Easily Adaptable for Clinical Use.

Journal: Stem cells and development

Published: December 17, 2024

Genetic Risk of Reticular Pseudodrusen in Age-Related Macular Degeneration: HTRA1 /lncRNA BX842242.1 dominates, with no evidence for Complement Cascade involvement.

Genetic Risk of Reticular Pseudodrusen in Age-Related Macular Degeneration: HTRA1 /lncRNA BX842242.1 dominates, with no evidence for Complement Cascade involvement.

Journal: medRxiv : the preprint server for health sciences

Published: October 14, 2024

HTRA1/lncRNA HTRA1-AS1 dominates in age-related macular degeneration reticular pseudodrusen genetic risk with no complement involvement.

HTRA1/lncRNA HTRA1-AS1 dominates in age-related macular degeneration reticular pseudodrusen genetic risk with no complement involvement.

Journal: Nature communications

Published: October 12, 2024

Derivation of two induced pluripotent stem cell lines from a healthy control subject.

Derivation of two induced pluripotent stem cell lines from a healthy control subject.

Journal: Stem cell research

Published: September 05, 2024

Cytokine Levels in Experimental Branch Retinal Vein Occlusion Treated With Either Bevacizumab or Triamcinolone Acetonide.

Cytokine Levels in Experimental Branch Retinal Vein Occlusion Treated With Either Bevacizumab or Triamcinolone Acetonide.

Journal: Translational vision science & technology

Published: June 20, 2024

Showing 1-12 of 73

Last Updated: 09/26/2026